7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.